AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung
cancer patients
Send a link to a friend
[June 05, 2023]
By Natalie Grover
LONDON (Reuters) - AstraZeneca's lung cancer therapy, Tagrisso, cut the
risk of death by more than half in patients with a certain form of lung
cancer who were diagnosed early enough to have their tumour surgically
removed, trial data showed.
Tagrisso is already the crown jewel in the Anglo-Swedish drugmaker's
portfolio, raking in $5.4 billion last year.
The drug has regulatory approvals across multiple geographies for
certain patients with so-called non small cell lung cancer (NSCLC) who
have a mutation of the EGFR gene.
The latest data, presented at the American Society of Clinical Oncology
(ASCO) meeting, establishes Tagrisso as the backbone treatment for EGFR-mutated
lung cancer, said Susan Galbraith, executive VP of oncology R&D at
AstraZeneca in a statement.
In a 682-patient trial called ADAURA, Tagrisso was evaluated against a
placebo in earlier-stage EGFR-mutated NSCLC patients who had undergone
surgery to remove their primary tumour.
The majority of such patients eventually see their cancer return despite
surgery and add-on chemotherapy.
![](http://archives.lincolndailynews.com/2023/Jun/05/images/ads/current/charrons_sda_PROMGRAD_2023.png)
In the trial, Tagrisso or a placebo was given to patients to assess
whether the AstraZeneca therapy could keep their cancer at bay.
Data showed Tagrisso slashed the risk of death by 51% compared to
placebo.
[to top of second column]
|
![](../images/060523PIX/health15.jpg)
Test tubes are seen in front of a
displayed AstraZeneca logo in this illustration taken, May 21, 2021.
REUTERS/Dado Ruvic/Illustration
![](http://archives.lincolndailynews.com/2023/Jun/05/images/ads/current/businessdirectory_dailycover_2023.png) "This is a pretty dramatic and
remarkable improvement," said Dave Fredrickson, executive vice
president of oncology at AstraZeneca in an interview with Reuters.
An estimated 88% of patients treated with Tagrisso were alive at
five years compared to 78% on placebo, trial data also showed.
Outside of chemotherapy, there are no drugs apart from Tagrisso that
have shown to help patients with EGFR-mutated lung cancer live
longer, Fredrickson highlighted, adding that there are probably a
third of eligible patients who are not yet being prescribed Tagrisso.
"We would hope that we would be able to use these data to be able to
close that gap," he said.
AstraZeneca is also expecting to provide details on the impact of
combining Tagrisso with chemotherapy in patients with advanced EGFR-mutated
lung cancer later this year.
(Reporting by Natalie Grover in London; Editing by Angus MacSwan)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |